English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 2/5 criteria met.
- ❌ Price trend failed
- ⚠️ Mixed growth
- ✅ Debt passed
- ❌ P/E failed
- ✅ Correction passed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2021 → 2022: -81.52%
Price change 2022 → 2023: -30.81%
Price change 2023 → 2024: 62.10%
Price change 2024 → 2025: -8.10%
Price change 2025 → 2026: 67.82%
Price change 2026 (year to date): 82.50%
Financial growth
Revenue CAGR (8 years): 11.79%
Earnings CAGR (8 years): N/A
Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.
Debt
Debt-to-equity ratio: 0.38
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 111.15
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 11.34% from the high over 6 months.
Correction between 10.0% and 20.0% (target range).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="PPGN.SW" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| PolyPeptide Group AG | 105.7 | 0.38 | +11.8 % | 🔒 |
| Azenta, Inc. | 93.0 | 0.06 | +0.0 % | – |
| ANI Pharmaceuticals, Inc. | 8.8 | 0.60 | +48.0 % | ★ 4/5 |
| Emeis | – | 6.11 | +11.4 % | – |
| Fleury S.A. | 16.6 | 1.05 | +16.2 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by PolyPeptide Group AG over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 250 m | 34.9 m | 14.0 % | n/a |
| 2021 | 315 m | 52.7 m | 16.8 % | +25.8 % |
| 2022 | 313 m | 8.7 m | 2.8 % | -0.4 % |
| 2023 | 357 m | -57.3 m | -16.1 % | +14.0 % |
| 2024 | 378 m | -21.8 m | -5.8 % | +5.7 % |
| 2025 | 437 m | -23.8 m | -5.4 % | +15.7 % |
Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.
Accounts and financial health
Balance sheet and cash flow published by PolyPeptide Group AG over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 136 m | 37.5 m | 95.7 m | 68.3 m | 74.5 m |
| Total Debt | 18.0 m | 21.2 m | 114 m | 94.1 m | 130 m |
| Net Debt | -118 m | -16.3 m | 18.0 m | 25.8 m | 55.9 m |
| Equity | 421 m | 422 m | 381 m | 357 m | 340 m |
| Total assets | 595 m | 576 m | 689 m | 757 m | 825 m |
| Operating cash flow | 57.4 m | 5.5 m | 36.5 m | 89.4 m | 78.0 m |
| Investments (capex) | 74.0 m | 75.1 m | 52.9 m | 85.8 m | 110 m |
| Free cash-flow | -16.6 m | -69.6 m | -20.2 m | 2.4 m | -30.4 m |
| Share buybacks | 5.5 m | 13.9 m | 0 | 0 | 487,160 |
| Dividends paid | 0 | 9.7 m | 0 | 0 | 0 |
Amounts in EUR, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Valuation and competitors
PolyPeptide Group AG compared with its sector on the same exchange and with its main competitors.
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 06/11/2026. Competitors: comparable companies named by the data provider.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about PolyPeptide Group AG
What is the PolyPeptide Group AG share price?
Latest recorded price: 40.05 CHF on 06/11/2026, for a market cap of 1.6 bn USD.
What is the revenue of PolyPeptide Group AG?
437 m USD for fiscal year 2025, with net income of -23.8 m USD (net margin -5.4 %).
What is the P/E ratio of PolyPeptide Group AG?
Trailing 12-month P/E of 100.8.
Is PolyPeptide Group AG stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN CH1110760852).
How many employees does PolyPeptide Group AG have?
1,362 full-time employees according to the latest published profile.
Who runs PolyPeptide Group AG?
Juan Jose Gonzalez is the company's chief executive.